

Psychopharmacology Bulletin

Contents

Vol. 19, No. 1

1983

	Page
Meeting Announcements	1
Book Reviews	2
Brief Report— Effects of Piracetam on Dyslexic's Verbal Conceptualizing Ability— <i>Colin Raymond Wilsher and Janet Milewski</i>	3
Articles— The Interrelationship Between Brain Noradrenergic and Dopaminergic Neuronal Systems in Regulating Animal Behavior: Possible Clinical Implications— <i>Adam Plaźnik and Wojciech Kostowski</i>	5
Results of a System to Monitor Effects of Psychotropic Medication in an Applied Setting— <i>John E. Kalachnik, Roger F. Miller, Ann G. Jamison, and Stuart R. Harder</i>	12
Number of Nonassessable Items and Cooperation Level of the Retarded During Systematic Dyskinesia Examinations— <i>John E. Kalachnik, Pat Kidd-Nielsen, and Stuart R. Harder</i>	16
EEG and EMG Monitored Electroconvulsive Therapy— <i>Peder Christensen and E. Hedemand</i>	20
Annual NCDEU Meeting (1982)—Abridged Proceedings— Adverse Drug Reactions in Psychopharmacology— Hepatotoxicity Associated With Phenothiazines— <i>Judith K. Jones, Stephen W. Van de Carr, Hyman Zimmerman, and Alda Leroy</i>	24
Evaluation of Nephrotoxicity in Affective Disorders Using Renal Enzymes— <i>Michael J. Garvey, Vicente B. Tuason, Charles H. Blomquist, and Sutae Hwang</i>	28
Coding and Analysis of Spontaneously Reported Symptoms in Clinical Trials— <i>Brian Tiplady, R.A. Elton, and John B. Loudon</i>	30
Assessment of Hemodialysis Treatment for Schizophrenia— The Experimental Use of Hemodialysis in a Double-Blind Study of 24 Chronic Schizophrenics— <i>Herbert Wagemaker, James L. Rogers, and Robert Cade</i>	33
Hemodialysis for Chronic Schizophrenia—A Double-Blind Study in Progress— <i>Rex Gentry, Hans Doerr, Robert Waters, David Dunner, and Belding H. Scribner</i>	37
Hemodialysis in Schizophrenia—An Evaluation— <i>William T. Carpenter, Jr., John H. Sadler, Paul D. Light, Thomas E. Hanlon, Albert A. Kurland, Manoel W. Penna, William P. Reed, Edwina H. Wilkinson, and John J. Bartko</i>	41
Clinical Assessment of Cognitive Functioning in the Aged— Naloxone Effects on Primary Degenerative Dementia (PDD)— <i>Barry Reisberg, Steven H. Ferris, Ravi Anand, Pervez Mir, Mony J. deLeon, and Eugene Roberts</i>	44
The Brief Cognitive Rating Scale (BCRS): Findings in Primary Degenerative Dementia (PDD)— <i>Barry Reisberg, Michael K. Schneck, Steven H. Ferris, Gerri E. Schwartz, and Mony J. deLeon</i>	47
A New Rating Scale for Geriatric Psychopharmacology— <i>Gerri E. Schwartz and Dieter M. Loew</i>	50
Anxiolytic Agents in the Treatment of Primary Medical Disorders— Abuse Potential of Antianxiety Drugs in Medical Practice— <i>Leo E. Hollister</i>	52

	Page
Treatment of the Anxiety Factor in Cardiovascular Disease— <i>David Wheatley</i>	53
Halazepam in the Treatment of Patients with Anxiety and Gastrointestinal Disorders— <i>David L. Earnest, Rodney M. Kazama, and L. Lizbeth Monroe</i>	55
Pharmacologic Treatment of Childhood Depressive Disorders—	
Childhood Depression: Imipramine Levels and Response— <i>Elizabeth B. Weller, Sheldon H. Preskorn, Ronald A. Weller, and Melissa Croskell</i>	59
Nortriptyline in Major Depressive Disorder in Children: Response, Steady-State Plasma Levels, Predictive Kinetics, and Pharmacokinetics— <i>Barbara Geller, James M. Perel, Edward F. Knitter, Helene Lycaki, and Zia Q. Farooki</i>	62
Imipramine Therapy of Depressed Children: Methodologic Considerations— <i>C. Keith Conners and Theodore Petti</i>	65
NCDEU Updates—	
Antidementia Drugs— <i>Thomas Crook</i>	69
Clinical Applications of Neuroleptic Blood Levels Measured by Radioreceptor Assay—	
Neuroleptic Concentrations in Schizophrenic Patients: Measurement by Radioreceptor Assay and Gas Chromatography— <i>Javaid I. Javaid, John M. Davis, Maurice W. Dysken, Philip Janicak, and Regina Casper</i>	72
Neuroleptic Levels by Radioreceptor Assay and Clinical Response During Treatment of Acute Exacerbation of Schizophrenia—Some Preliminary Findings— <i>Jonathan S. Greenberg, Walter A. Brown, Thomas P. Laughren, and Jamie Krantz</i>	74
Serum Neuroleptic Levels in the Maintenance Treatment of Schizophrenia— <i>Walter A. Brown and Thomas Laughren</i>	76
Free Communications—Session A—	
Long-Term Therapeutic Efficacy and Drug-Related Abnormal Movements: A Prospective Study of Haloperidol in Autistic Children— <i>Magda Campbell, Richard Perry, Walter G. Bennett, Arthur M. Small, Wayne H. Green, Dennis Grega, Victor Schwartz, and Lillian Anderson</i>	80
Left-Side Visual Neglect in ECT Patients— <i>Harold A. Sackeim, Stephanie Portnoy, Paolo Decina, Sidney Malitz, Valerie Warmflash, William A. Vingiano, and Stuart C. Yudofsky</i>	83
Prognostic Value of Serial Dexamethasone Suppression Tests During and Following ECT— <i>Paolo Decina, Harold A. Sackeim, and Sidney Malitz</i>	85
The Dexamethasone Suppression Test During Depression, and Following Recovery From a Depressive Episode— <i>Eric D. Peselow, Ngaere Goldring, Ronald R. Fieve, and Ruth Wright</i>	87
The Hamilton Depression Scale: Factor Scoring and Profile Classification— <i>Howard M. Rhoades and John E. Overall</i>	91
Pharmacoe-EEG Study of 6-Azamianserin (ORG 3770): Dissociation of EEG and Biochemical Predictors of Antidepressant Activity— <i>Max Fink and Peter Irwin</i>	96
Open-Label Studies of Adinazolam in Severe Depression— <i>Robert E. Pyke, Jay B. Cohn, John P. Feighner, and Ward T. Smith</i>	96
A Controlled Clinical Trial Between Amitriptyline and Its N-Oxide Metabolite— <i>Giovanni B. Cassano, Luciano Conti, Gabriele Massimetti, Pantaleo Fornaro, and Fosca Re</i>	98
Cyproheptadine, An Antidepressant and Weight-Inducing Drug for Anorexia Nervosa— <i>Katherine A. Halmi, Elke Eckert, and James R. Falk</i>	103
Dosages and Serum Levels of Amitriptyline in Depressed Outpatients Under Routine Treatment Conditions. Supporting Low-Dose Therapy?— <i>M. Linden, B. Müller-Oerlinghausen, G. Schüssler, and H. Wilke-Burger</i>	106
Rapidity of Symptom Reduction in Depressed Outpatients Treated with Amitriptyline, Perphenazine, and Amitriptyline/Perphenazine— <i>Brigitte A. Prusoff and Gerald L. Klerman</i>	109

Autonomic Effects of Fluvoxamine Versus Amitriptyline, Doxepin, and Placebo— <i>William H. Wilson, Harufusa Higano, John Papadatos, Surendra Kelwala, and Thomas A. Ban</i>	111
Free Communications—Session B—	
Effects of the GABA Agonist THIP on Chronic Anxiety Patients— <i>Rudolf Hoehn-Saric</i> ..	114
Alprazolam in the Treatment of Anxiety and Panic Disorders— <i>Guy Chouinard, Lawrence Annable, Rejean Fontaine, and Leslie Solyom</i>	115
Agoraphobia: Behavioral and Pharmacological Treatment ($N = 49$)— <i>Matig Mavissakalian and Larry Michelson</i>	116
Comparison of Affects in Parkinson's Disease and Schizophrenia— <i>Murray Alpert and Michael Rush</i>	118
Psychotropic Drug History and Tardive Dyskinesia— <i>Marc H. Branchey, Mary Ann Richardson, and Carole Siegel</i>	120
A Placebo-Controlled Trial of L-DOPA in Tardive Dyskinesia— <i>Henry A. Nasrallah, Frederick J. Dunner, Robert E. Smith, and Mona McCalley-Whitters</i>	122
Lecithin Plus Lithium in Tardive Dyskinesia— <i>Brian G. Anderson, Dean Reker, Miriam Banay-Schwartz, Ethel Webb, and Jan Volavka</i>	124
Lecithin and Piracetam in Alzheimer's Disease— <i>Michael Serby, June Corwin, John Rotrosen, Steven H. Ferris, Barry Reisberg, Eitan Friedman, Kathleen A. Sherman, Barbara Jordan, and Raymond Bartus</i>	126
Comparison of Imipramine and Benztrapine in the Prevention of Extrapyramidal Side Effects of Fluphenazine— <i>Samuel G. Siris, Arthur E. Rifkin, Gerard T. Reardon, and Margaret November</i>	129
Serum Levels of Fluphenazine: Effect of Dosage and Route of Administration and Relation to Side Effects and Clinical Response— <i>Javier I. Escobar, Allistair Barron, and Ramzi Kiriakos</i>	131
Therapeutic Efficacy of Cholecystokinin in Neuroleptic-Resistant Schizophrenic Subjects— <i>N.P.V. Nair, D.M. Bloom, J.N. Nestoros, and G. Schwartz</i>	134
Fluspirilene in the Treatment of Newly Admitted Schizophrenic Patients— <i>Guy Chouinard and Lawrence Annable</i>	136
The Current Status of Clozapine— <i>James L. Claghorn, Faruk S. Abuzzahab, Sr., Richard Wang, Craig Larson, Alan J. Gelenberg, Gerald L. Klerman, Vicente Tuason, and Richard Steinbook</i>	128
Cumulative Index—Psychopharmacology Bulletin—1982	141
Psychopharmacology—A Recurring Bibliography—	
Subject Section	S-1
Author Section	A-57